MBX Biosciences, Inc. (MBX)
$63.00-$3.39 (-5.11%) Today
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 370 | $24K |
| Grant or award | 11 | 647,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
28 Form 4 filings on record, the earliest from Jun 5, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Salomon Azoulay - Officer | Open-market sale | Common Stock | 370 | $65.77 | $24K | |
 John W. Smither - Officer | Grant or award | Common Stock | 28,000 | $0.00 | - | |
| John W. Smither - Officer | Grant or award | Stock option (right to buy) | 130,000 | $0.00 | - | |
| Steven L. Hoerter - Officer | Grant or award | Common Stock | 71,000 | $0.00 | - | |
| Steven L. Hoerter - Officer | Grant or award | Stock option (right to buy) | 331,000 | $0.00 | - | |
| Edward T. Mathers | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Ora H. Pescovitz | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Patrick J. Heron | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Laurie Stelzer | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Steven L. Hoerter | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Steven Ryder | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Tiba Aynechi | Grant or award | Stock option (right to buy) | 12,500 | $0.00 | - | |
| Salomon Azoulay - Officer | Option exercise | Common Stock | 55,000 | $10.46 | $575K | |
| Salomon Azoulay - Officer | Open-market sale | Common Stock | 55,000 | $38.38 | $2.11M | |
| Salomon Azoulay - Officer | Option exercise | Common Stock | 15,003 | $16.00 | $240K | |
| Salomon Azoulay - Officer | Open-market sale | Common Stock | 15,003 | $38.30 | $575K | |
| Salomon Azoulay - Officer | Option exercise | Stock option (right to buy) | 55,000 | $0.00 | - | |
| Salomon Azoulay - Officer | Option exercise | Stock option (right to buy) | 15,003 | $0.00 | - | |
| Salomon Azoulay - Officer | Open-market sale | Common Stock | 231 | $29.54 | $7K | |
| P. Kent Hawryluk - Officer | Open-market sale | Common Stock | 607 | $29.54 | $18K | |
| Steven L. Hoerter | Grant or award | Common Stock | 11,938 | $0.00 | - | |
| Steven L. Hoerter | Grant or award | Stock option (right to buy) | 74,249 | $0.00 | - | |
| Steven L. Hoerter | Grant or award | Stock option (right to buy) | 0 | $0.00 | - | |
| P. Kent Hawryluk - Officer | Open-market purchase | Common Stock | 18,500 | $28.41 | $526K | |
| P. Kent Hawryluk - Officer | Option exercise | Common Stock | 28,768 | $16.00 | $460K | |
| P. Kent Hawryluk - Officer | Option exercise | Stock option (right to buy) | 28,768 | $0.00 | - | |
| Salomon Azoulay - Officer | Grant or award | Common Stock | 15,000 | $0.00 | - | |
| Salomon Azoulay - Officer | Grant or award | Stock option (right to buy) | 70,000 | $0.00 | - | |
| Richard Bartram - Officer | Grant or award | Common Stock | 15,000 | $0.00 | - | |
| Richard Bartram - Officer | Grant or award | Stock option (right to buy) | 70,000 | $0.00 | - | |
| P. Kent Hawryluk - Officer | Grant or award | Common Stock | 35,250 | $0.00 | - | |
| P. Kent Hawryluk - Officer | Grant or award | Stock option (right to buy) | 164,500 | $0.00 | - | |
| Laurie Stelzer | Grant or award | Stock option (right to buy) | 32,000 | $0.00 | - | |
| Steven L. Hoerter | Grant or award | Stock option (right to buy) | 8,000 | $0.00 | - | |
| Steven L. Hoerter | Grant or award | Stock option (right to buy) | 100,000 | $0.00 | - | |
| P. Kent Hawryluk - Officer | Option exercise | Common Stock | 182,859 | $3.25 | $594K | |
| P. Kent Hawryluk - Officer | Option exercise | Stock option (right to buy) | 182,859 | $0.00 | - | |
| P. Kent Hawryluk - Officer | Open-market purchase | Common Stock | 20,000 | $13.64 | $273K | |
| Steven L. Hoerter | Open-market purchase | Common Stock | 20,000 | $13.25 | $265K | |
| Patrick J. Heron | Open-market purchase | Common Stock | 666,666 | $18.00 | $12.00M | |
| James M. Cornelius | Grant or award | Stock option (right to buy) | 16,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Hawryluk P. Kent | Former Officer | 3,745 | $256K | View on EDGAR | |
| Hawryluk P. Kent | Officer | 936 | $62K | View on EDGAR | |
| Azoulay Salomon | Officer | 370 | $24K | View on EDGAR |
MBX Biosciences, Inc. (MBX) had 10 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for MBX runs to 28 Form 4 filings, the earliest from 2025-06-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MBX were filed in the last 90 days. 4 purchases are on record for this company.
1 insider sale of MBX was filed in the last 90 days, totaling $24K.
This page tracks MBX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MBX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
